PDCD1 and neoplasm: Currently, invasive biopsies are the gold standard for evaluating the status of PD-1, but these methods have several limitations, including sampling bias due to tumor heterogeneity, a slow process, and high costs, and they may fail to produce actionable results due to insufficient quantity or the quality of the tissue [20].